The United States Patent and Trademark Office (USPTO) recently issued the exclusive protection and approval for FAMU CoPPS, IPH Professor and Eminent Scholar Chair in Biomedical Sciences, Dr. Seth Ablordeppey’s patent titled: “Alkylated tetrahydroisoquinolines for binding to central nervous system receptors.” Patent number: 10525050
According to the Centers for Disease Control and Prevention (CDC), over 750,000 people have died since 1999 from a drug overdose, and two-thirds of drug overdose deaths in 2018 involved an opioid pain killer. Overdose deaths involving opioids have increased almost six times since 1999. Overdoses involving opioids killed nearly 47,000 people in 2018, and 32% of those deaths involved prescription opioids. Thus, there is an urgent need to find new targets for drug development as alternatives to opioids as pain medications.
Dr. Ablordeppey’s research laboratory has been working on finding new drugs that target a receptor demonstrated with the potential for developing novel pain medications, medications to treat drug abuse and addiction, and even certain sleep disorders.
The present invention refers to the discovery of 5-HT7 receptor agonists with the potential to treat pain and the symptoms of pain, especially certain subtypes of pain like neuropathic and inflammatory pain and even certain sleep disorders. The specific compounds are novel agents that selectively activate the 5-HT7 receptor with a significant bias for recruiting β-arrestin to the receptor. These compounds have laid the foundation for further characterization of the 5-HT7 receptor and its potential use in multiple treatments, including replacement of current pain medications, treatment of drug abuse and addiction, psychiatric illnesses, and certain types of sleep disorders.
Dr. Ablordeppey holds five U.S. patents, including this one, and two WIPO patents.